TP53 and myelodysplastic syndrome: A cornerstone trial of decitabine for adult patients with AML/MDS demonstrated a surprising result: patients with TP53 mutation showed a remarkably higher response rate than patients without TP53 mutation (100% (21/21) vs. 41% (32/78), p < 0.001) [67].